Ischemic stroke market Size 2022: Global Market Trends, Regional Demand and Growth Forecast to 2026
Prevalence of Diabetes Expected to Push the Demand for the Global
Ischemic Stroke Market
Ischemic Strokes occur
when an artery or blood vessel supplying blood to the brain is blocked. The
brain is dependent on the arteries to bring fresh blood from the lungs and
heart. A blockage in the same causes ischemic stroke. The underlying reason
behind such obstruction is the development of fatty deposits lining the vessel
walls, also known as atherosclerosis.
A research by the World
Health Organization (WHO) states that around 17 million deaths have been
noticed annually due to strokes. The higher mortality rate associated with
strokes showcases an impending need for new and innovative drugs and diagnostic
devices. As per the latest report released by Market Research Future (MRFR),
the Global Ischemic
Stroke Market is expected to attain a CAGR of approximately 8.3% during the
forecast period between 2017 and 2023.
The evolving lifestyle of
individuals, prevalence of diabetes, increasing ageing population, and high
tobacco usage are the major factors driving the market. Additionally, the
increasing demand for minimally invasive procedures and advancements in
surgical procedures are some of the key factors accelerating the growth of the
global market. However, the high cost associated with such surgical procedures
and the excessive medicinal usage for the treatment of the condition is
reported as a major hindrance to the market growth.
Sample Report: https://www.marketresearchfuture.com/sample_request/5423
Market
Segmentation
The Global Ischemic Stroke
Market segmentation is based on key dynamics like drug class, diagnosis,
end-users, and surgery.
By drug class, the market
segments into anticoagulant, tissue plasminogen activator, antihypertensive,
antiplatelet, and others.
By diagnosis, the market
includes carotid ultrasound Computed Tomography (CT), echocardiography,
cerebral angiography, Magnetic resonance imaging (MRI), electrocardiography,
and others.
By end-user, the market
comprises of medical institutes, research organizations, hospitals &
clinics, and others.
By surgery, the market
divides into endovascular mechanical thrombectomy, carotid endarterectomy, and
angioplasty.
Regional
Analysis
The Global Ischemic Stroke
Market is geographically segmented into the following regions: Asia Pacific,
America, Europe, and the Middle East and Africa.
The Americas is reported
to be the largest market for ischemic stroke due to technological innovations,
favorable government initiatives, and rising demand for ischemic stroke
products.
Europe holds the second
largest share of the market and is expected to hold on to the same in the
forthcoming years due to numerous factors. Rising prevalence of acute ischemia
stroke cases and advancements in the surgical device technology are two key
factors driving the market herein. Other driving factors of the market in this
region is the growing number of diabetes mellitus population primarily in the
developed nations of Europe.
Asia Pacific is identified
to witness the most promising growth in the forecast period to cement its place
in the global ischemic stroke market. The proliferating growth of the region
can be attributed to the widespread prevalence of stroke cases in the Asia
Pacific region. Both China and India are two of the major contributors to the
regional market and will play major roles in accelerating the overall Asia
Pacific region. Manufacturers are quickly realizing the potential this region
holds and are expanding their operations therein to capitalize on the same.
The Middle East region is
anticipated to grow at a fast rate owing to factors like increasing emphasis on
research and development activities in the healthcare sector and continuous
development of the healthcare infrastructure.
Competitive
Landscape
The Global Ischemic Stroke
Market includes numerous prominent players like Stryker Corporation (U.S.),
Johnson & Johnson (U.S.), Abbott Laboratories (U.S.), Genentech, Inc.
(U.S.), Merck & Co., Inc. (U.S.), Sanofi (France), Bayer AG (Germany),
Koninklijke Philips N.V. (Netherland), Boston Scientific Corporation (U.S.),
Medtronic plc (U.S.), Siemens Healthcare (U.S.), Pfizer Inc. (U.S.), GE
Healthcare (U.S.), Covidien PLC (Ireland), GE Healthcare (U.S.), Philips
Healthcare (U.S.), Hitachi, Ltd (Japan), Boehringer Ingelheim (Germany),
Penumbra, Inc. (U.S.), Cordis Corporation (U.S.), Daiichi Sankyo (U.S.),
Biogen (U.S.), and others.
October 25th, 2018, it was
revealed at the ASN Kidney Week 2018, that patients with late-stage chronic
kidney disorder who are receiving the treatment of warfarin were the most
probable to experience cerebrovascular accidents like transient ischemic attack
or ischemic stroke. The study was undertaken by the University of Tennessee
Health Science Center.
Access Report Details @ https://www.marketresearchfuture.com/reports/ischemic-stroke-market-5423
Related Report:
Dysmenorrhea
Treatment Market Research Report- Global Forecast to 2027
Syringe
and Needle Market Research Report - Global Forecast to 2027
Global
Medical Robotics Market Research Report- Forecast To 2027
Global
Neuromodulation Devices Market Research Report- Forecast To 2027
Global
Erythropoietin Drug Market Research Report- Forecast To 2027
About US:
Market
Research Future (MRFR) enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson
Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment